<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700280</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG3970-CL-207</org_study_id>
    <secondary_id>2020-003298-22</secondary_id>
    <nct_id>NCT04700280</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome</brief_title>
  <acronym>GLIDER</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3970 for 12 Weeks in Adult Subjects With Active Primary Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first exploration of GLPG3970 in subjects with active primary Sjogren's Syndrome to&#xD;
      evaluate the efficacy, safety and tolerability and determine its pharmacokinetics (PK)&#xD;
      profile compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Treatment-emergent Adverse Events (TEAEs) by Severity</measure>
    <time_frame>From first dose up to Follow-up (Week 16)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Weeks 4, 8, and 12</measure>
    <time_frame>Baseline, Weeks 4, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EULAR ESSDAI Score Over Time at Weeks 4, 8, and 12</measure>
    <time_frame>Baseline, Weeks 4, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Plasma Trough Concentration (Ctrough) of GLPG3970</measure>
    <time_frame>Predose (within 30 minutes prior to dosing) on Days 8, 29, 57, and 85</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Primary Sjögren Syndrome</condition>
  <arm_group>
    <arm_group_label>GLPG3970</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GLPG3970 tablet, orally, once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo tablet, orally, once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3970</intervention_name>
    <description>GLPG3970 film-coated tablet.</description>
    <arm_group_label>GLPG3970</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo film-coated tablet.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Documented diagnosis of primary Sjögren's Syndrome (pSS) for &lt;10 years prior to&#xD;
             screening AND defined by the classification criteria &gt;=4 described by the American&#xD;
             College of Rheumatology - European League Against Rheumatism (ACR-EULAR).&#xD;
&#xD;
          2. Participant has an ESSDAI score &gt;=5 assessed on 7 domains: constitutional,&#xD;
             lymphadenopathy, glandular, articular, cutaneous, hematological, and biological.&#xD;
&#xD;
          3. Participant has an ESSPRI score &gt;=5.&#xD;
&#xD;
          4. Participant has stimulated whole salivary flow rate of &gt;=0.1 mL/min.&#xD;
&#xD;
          5. Participant has positive serum titers of anti-Sjögren's-syndrome-related antigen A&#xD;
             (anti-SS-A)/Ro and/or anti-SS-B/La antibodies.&#xD;
&#xD;
          6. Participants already on treatment should be on stable standard of care (SoC) for at&#xD;
             least 4 weeks prior to first investigational product (IP) dosing.&#xD;
&#xD;
             The following SoC medications are permitted:&#xD;
&#xD;
               -  Corticosteroids &lt;=7.5 mg/day (prednisone or equivalent); AND/OR&#xD;
&#xD;
               -  Non-steroidal anti-inflammatory drugs (NSAIDs); AND/OR&#xD;
&#xD;
               -  One single antimalarial at a stable dose (hydroxychloroquine &lt;=400 mg/day;&#xD;
                  quinacrine 100 mg/kg/day, or chloroquine &lt;=250 mg/day); AND/OR&#xD;
&#xD;
               -  One single immunosuppressant at a stable dose (methotrexate [MTX] &lt;=10 mg/week or&#xD;
                  azathioprine [AZA] &lt;=2 mg/kg/day); AND/OR&#xD;
&#xD;
               -  One single cholinergic stimulant at a stable dose (e.g., pilocarpine,&#xD;
                  cevimeline).&#xD;
&#xD;
          7. Female participant of childbearing potential must have a negative highly sensitive&#xD;
             (serum beta human chorionic gonadotropin or urine dipstick) pregnancy test.&#xD;
&#xD;
          8. Female participant of childbearing potential or male participant must agree to use&#xD;
             highly effective contraception/preventive exposure measures.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Secondary Sjögren's syndrome according to the ACR-EULAR (2016) classification.&#xD;
&#xD;
          2. History or presence of unstable condition not related to Sjögren's Syndrome that, in&#xD;
             the opinion of the investigator, could constitute an unacceptable risk when taking the&#xD;
             IP or interfere with the interpretation of data.&#xD;
&#xD;
          3. Participant has any active systemic infection within 2 weeks prior to first IP dosing,&#xD;
             or poorly controlled chronic cardiac, pulmonary, or renal disease.&#xD;
&#xD;
          4. Participant has a known or suspected history of or a current immunosuppressive&#xD;
             condition, or a history of opportunistic infections (e.g., human immunodeficiency&#xD;
             virus [HIV] infection, histoplasmosis, listeriosis, coccidioidomycosis,&#xD;
             pneumocystosis, aspergillosis).&#xD;
&#xD;
          5. Participant has a chronic hepatitis B virus (HBV) infection, as defined by persistent&#xD;
             HBV surface antigen (HBsAg) positivity. Participant has hepatitis C virus (HCV)&#xD;
             infection, as defined by positive HCV antibody at screening and detectable HCV&#xD;
             viremia. Participants with positive HCV antibody must undergo reflex HCV ribonucleic&#xD;
             acid (RNA) testing, and participants with HCV RNA positivity will be excluded.&#xD;
             Participants with positive HCV antibody and negative HCV RNA are eligible.&#xD;
&#xD;
          6. Participant testing positive for severe acute respiratory syndrome coronavirus 2&#xD;
             (SARS-CoV-2) infection as detected at screening based on real time polymerase chain&#xD;
             reaction (RT-PCR) or at baseline based on immunoglobulin M (IgM) immunoassay, or&#xD;
             participants who have been in contact with SARS-CoV-2 infected individuals in the 2&#xD;
             weeks prior to first dosing of IP. Participants presenting any signs or symptoms of&#xD;
             SARS-CoV-2 infection, as detected prior to first IP dosing following careful physical&#xD;
             examination (e.g., cough, fever, headaches, fatigue, dyspnea, myalgia, anosmia,&#xD;
             dysgeusia, anorexia, sore throat, etc). In addition, any other locally applicable&#xD;
             standard diagnostic criteria may also apply to rule out SARS-CoV-2 infection.&#xD;
&#xD;
          7. Participant has taken any disallowed therapies:&#xD;
&#xD;
               -  Mycophenolate mofetil (MMF) within a week prior to screening.&#xD;
&#xD;
               -  Cyclosporine/Tacrolimus within a week prior to screening.&#xD;
&#xD;
               -  Cyclophosphamide within 6 months prior to screening.&#xD;
&#xD;
               -  Ocular medicines (e.g., topical cyclosporine, topical NSAIDs/ corticosteroids)&#xD;
                  for at least 4 weeks prior to screening, except for a sporadic use.&#xD;
&#xD;
               -  Biologics such as, but not limited to, rituximab, abatacept, and any other&#xD;
                  unapproved biologic within 6 months prior to screening.&#xD;
&#xD;
               -  Plasmapheresis within 12 weeks prior to screening.&#xD;
&#xD;
               -  Plasma exchange within 12 weeks prior to screening.&#xD;
&#xD;
               -  Intravenous immunoglobulin (IVIG) therapy within 24 weeks prior to screening.&#xD;
&#xD;
               -  Other prohibited medications within 2 weeks or 5 half-lives, whichever is longer,&#xD;
                  prior to first IP dosing.&#xD;
&#xD;
          8. Concurrent use of anticholinergic agents or any other medication known to cause dry&#xD;
             mouth/dry eyes that, in the opinion of the investigator, are a contributing factor to&#xD;
             the participant's dryness and/or use of anticholinergic agents not contributing to&#xD;
             this dryness, if not stable at least 4 weeks prior to screening.&#xD;
&#xD;
          9. Participant has a history of tuberculosis (TB) diagnosis or evidence of active or&#xD;
             latent infection with Mycobacterium tuberculosis.&#xD;
&#xD;
         10. Participant has a history of lymphoma or any malignancy within the past 5 years prior&#xD;
             to screening with the exception of excised and curatively treated non-metastatic basal&#xD;
             cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of cervix&#xD;
             which is considered cured with minimal risk of recurrence.&#xD;
&#xD;
         11. Participant has severe organ manifestation or life-threatening condition, or has&#xD;
             planned a surgery during the study.&#xD;
&#xD;
        Note: Other protocol-defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Vincent</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Galapagos Medical Information</last_name>
    <phone>+3215342900</phone>
    <email>medicalinfo@glpg.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe Hospitalier Pellegrin - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nice Hôpital L'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg - Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite - Universitatsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens Laiko</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Obudai Egeszsegugyi Centrum Kft</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 2 im.dr J. Biziela</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Plejady</name>
      <address>
        <city>Krakow</city>
        <zip>30-363</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ETG Lublin</name>
      <address>
        <city>Lublin</city>
        <zip>20-412</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych S.C.</name>
      <address>
        <city>Poznań</city>
        <zip>60-773</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medycyna Kliniczna</name>
      <address>
        <city>Warsaw</city>
        <zip>00-874</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Medyczne Reuma Park</name>
      <address>
        <city>Warsaw</city>
        <zip>02-691</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Harmoniya Krasy</name>
      <address>
        <city>Kyiv</city>
        <zip>1135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Sjögren Syndrome</keyword>
  <keyword>Sjögren Syndrome</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Rheumatic Diseases</keyword>
  <keyword>Sicca Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

